IPS Heart’s ISX9-CPC received FDA rare pediatric drug designation for cardiomyopathies associated with dystrophinopathies. The move recognizes the program’s relevance to a subset of pediatric patients with serious disease and can unlock incentives that support clinical development planning. For sponsors in neuromuscular cardiomyopathy and gene/cell therapy-adjacent areas, the designation can be a signal of the FDA’s willingness to engage early on rare pediatric endpoints and trial designs. While designation does not guarantee eventual approval, it typically strengthens the regulatory strategy—especially for rare disease programs competing for limited pediatric trial resources.